Therapeutic Drug Monitoring of Risankizumab in Psoriasis Patients (BIOLOPTIM-RIS)

Launched by UNIVERSITY HOSPITAL, GHENT · Jan 5, 2023

Keywords

ClinConnect Summary

This clinical trial, called BIOLOPTIM-RIS, is studying how to better monitor the drug risankizumab in patients with psoriasis vulgaris, which is a common form of psoriasis that causes raised, red patches on the skin. Risankizumab is a type of biologic medication that is very effective for treating moderate to severe psoriasis, but it can be expensive, and current treatment plans often use a “one dose fits all” approach. The researchers want to find out if checking the levels of risankizumab in the blood early on can help determine the best dose for each patient, minimizing the risk of giving too much or too little medication.

To participate in this trial, individuals must have been diagnosed with chronic plaque-type psoriasis and agree to take part in the study by signing an informed consent form. However, those with other forms of psoriasis, pregnant or nursing individuals, or those who cannot have multiple blood draws will not be eligible. If you join the study, you can expect to have regular blood tests to measure the medication levels and help find the best treatment plan for you. Overall, this research aims to improve the way risankizumab is used, ensuring that patients receive the most effective and personalized care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants must have a clinical or histological diagnosis of chronic plaque-type psoriasis
• • Participants must sign an ICF indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study.
• Exclusion Criteria:
• • Participants who have currently a predominant nonplaque form of psoriasis
• • Participants who are pregnant, nursing or planning a pregnancy
• • Participants who are unable or unwilling to undergo multiple venapunctures
• • Participants who are treated according to a different dosing schedule than standard dosing of risankizumab